Rare case of mantle cell lymphoma of the lacrimal sac

ABSTRACT Mantle cell lymphoma of the ocular and periorbital regions is extremely rare but should be considered in the differential diagnosis of lesions affecting the periorbital tissues. In this study, we present a rare case of mantle cell lymphoma of the lacrimal sac in a 65-year-old male presenting with a mass in the lacrimal sac region and epiphora. After clinical examinations and imaging studies, the mucocele was misdiagnosed. Considering the unexpected findings during external dacryocystorhinostomy, a frozen biopsy was performed, which confirmed the diagnosis of lymphoma.

Remisión de la psoriasis vulgar posterior a quimioterapia por neoplasia hematológica / Remission of psoriasis after chemotherapy for hematological malignancy

RESUMEN Divulgamos el caso de una paciente con psoriasis vulgar que presento empeoramiento de la misma luego de infección por Chikungunya, sin mejoría del brote con el tratamiento habitual de la psoriasis, en quien posteriormente se realiza el diagnóstico de Linfoma Hodgkin tipo clásico. Se inició tratamiento quimioterápico y se observó una mejoría completa de las lesiones cutáneas de la psoriasis.

ABSTRACT We report the case of a patient with psoriasis vulgaris who presented worsening of the disease after infection with Chikungunya, with no improvement of the outbreak with the usual treatment for psoriasis, in whom a diagnosis of classic Hodgkin lymphoma was subsequently made. Chemotherapy treatment was started and a complete improvement of the skin lesions of psoriasis was observed.

Inborn errors of immunity and its clinical significance in children with lymphoma in China: a single-center study

Abstract Objective: To investigate the incidence, clinical and genetic characteristics of pediatric lymphoma patients of China with inborn errors of immunity (IEI)-related gene mutations, which have not been fully studied. Method: From Jan. 2020 to Mar. 2023, IEI-related genetic mutations were retrospectively explored in 108 children with lymphomas admitted to Beijing Children's Hospital by NGS. Genetic rule and clinical characteristics as well as treatment outcomes were compared between patients with or without IEI-related gene mutations. Results: A total of 17 patients (15.7 %) harbored IEI-associated mutations, including 4 cases with X-linked lymphoproliferative syndrome (XLP), 3 cases had mutations in tumor necrosis factor receptor superfamily 13B (TNFRSF13B), 2 cases with Activated p110 syndrome (APDS). Patients with IEI all had alteration of immunocompetence with decreased levels of immunoglobulin and lymphocyte subsets. Recurrent infection existed in 41.2 % of patients. The 18-month event-free survival (EFS) and the overall response rate (ORR) of patients with IEI are significantly lower than those without IEI (33.86% vs. 73.26 %, p = 0.011; 52.94% vs. 87.91 %, p = 0.002, respectively). In addition, patients with IEI had a higher progression disease (PD) rate of 23.5 % than those without IEI of 4.4% (p = 0.006). Conclusion: The present study demonstrated that IEI-associated lymphomas were much more common than originally appreciated in pediatric lymphomas, and those were insensitive to treatment and more likely to progress or relapse. The genomic analysis and a thorough review of the medical history of IEI can be used to distinguish them from pediatric lymphomas without IEI, which are beneficial for the early diagnosis and direct intervention.

Transient synovitis of hip joint following COVID-19 infection in a child with Hodgkins lymphoma

Transient synovitis is a common cause of hip pain in children. COVID-19 pandemic affected pediatric cancer patients more often that general pediatric population. COVID-19 has been associated with various musculoskeletal symptoms including synovitis. Radiological assessment of these symptoms can contribute significantly in management of such patients. We report a case of transient synovitis of hip joint following COVID-19 infection in a 10-year-old boy with Hodgkins抯 lymphoma. He presented with fever and myalgia, found to be positive for COVID-19, managed conservatively. Two weeks later presented with right hip pain and limping. He was found to have restricted joint mobility and hip tenderness. Magnetic resonance imaging (MRI) pelvis was done which showed minimal right hip effusion and synovial thickening and enhancement. He was managed conservatively and recovered completely.

Non-Hodgkins lymphoma of bilateral eyelids with basal cell carcinoma of nose: a rare case report

Malignant tumours affecting the eyelid mainly include basal cell carcinoma. Non-Hodgkin抯 lymphoma may occur in almost any part of the body and should be considered in the differential diagnosis of extra lymphoid tumours. Non- Hodgkin抯 lymphoma of the eyelid is rare. Rare diseases should be considered in differential diagnoses because they have the tendency for rapid systemic involvement and they may require treatments that are different from the other common diseases. Basal cell carcinoma occurs most frequently at sun-exposed sites, most commonly in the head and neck regions. The aim of any therapy selected for BCC treatment involving the head and neck is to ensure complete removal, functional preservation, and a good cosmetic outcome. Here, we reported a case of a 70-year-old female with non-Hodgkin lymphoma of eyelids followed by basal cell carcinoma of the nose treated with multimodality approach.

Effective geriatric management strategies for fatal non-Hodgkin lymphoma: Insights from a case report / Estrategias geriátricas efectivas para el tratamiento del linfoma no Hodgkin mortal: conclusiones de un estudio de caso

This case report delves into the intricate medical history of an 85-year-old male who experienced a myriad of health challenges throughout his years. With a medical history full of conditions, such as stroke, sinus bradycardia, chronic obstructive pulmonary disease, severe pulmonary hypertension, and chronic gastritis, the patient´s health profile is further complicated by prostatic hypertrophy, persistent dorsalgia and lumbalgia, the presence of a thyroid nodule, and a recent onset of hypothyroidism. Among the diverse medical conditions of this patient, our narrative is primarily centered on his latest diagnosis: non-Hodgkin´s lymphoma. Non-Hodgkin´s lymphoma is not just a mere addition to his already complex medical history; it is a malignant neoplasm that shapes worldwide patterns of cancer mortality. The first indicators that led to this discovery were the patient´s complaints of persistent pain in the left lateral neck region associated with dysphagia. This was not an isolated symptom; the patient also reported a month-long history of asthenia, myalgias, weakness around the pelvic girdle, fatigue, and hyporexia, depicting a concerning clinical picture. Advanced diagnostic tools, namely ultrasound and computed tomography, shed light on submaxillary and cervical adenopathies. To corroborate such findings and get a definitive diagnosis of malignancy, a fine-needle aspiration was advised. Through this case, we aim not only to describe a clinical scenario but to highlight the challenges involved in the diagnosing and treatment of non-Hodgkin ´s lymphoma, especially in elderly patients. The overlap of multiple comorbidities adds further complexity to the scene, demanding meticulous care and expertise. This report serves as an educational tool for oncology experts, as well as testimony to the complexities of patient care in the oncology diagnostic and treatment setting.

Este reporte de caso se centra en el intricado historial médico de un varon de 85 años que experimenta una miriada de problemas de salud a lo largo de sus años. Con un historial médico lleno de afecciones, como accidente cerebrovascular, bradicardia sinusal, enfermedad pulmonar obstructiva crónica, hipertensión pulmonar grave y gastritis crónica, el perfil de salud del paciente se complica aún más por la presencia de hipertrofia prostática, dorsalgia y lumbalgia persistentes, la presencia de un nódulo tiroideo y el reciente diagnóstico de hipotiroidismo. Entre las diversas afecciones de este paciente, nuestra narración se centra principalmente en su último diagnóstico: linfoma no Hodgkin. El linfoma no hodgkiniano no es un mero añadido a su ya complejo historial médico; es una neoplasia maligna que configura las tendencias de mortalidad por cáncer a nivel mundial. Los primeros indicadores que llevaron a este descubrimiento fueron las quejas del paciente por dolor persistente en la región lateral izquierda del cuello, asociado a disfagia. No se trataba de un síntoma aislado, ya que el paciente también refería desde hacía un mes astenia, mialgias, debilidad alrededor de la cintura pélvica, fatiga e hiporexia, lo que describía un cuadro clínico preocupante. Las herramientas diagnósticas avanzadas, a saber, la ecografía y la tomografía computarizada, arrojaron luz sobre las adenopatías submaxilares y cervicales. revelaron sobre las adenopatías submaxilares y cervicales. Para corroborar tales hallazgos y obtener un diagnóstico definitivo de malignidad, se aconsejó una aspiración con aguja fina. A través de este caso, pretendemos no sólo describir un escenario clínico, sino resaltar los retos que implica el diagnóstico y tratamiento del linfoma no Hodgkin, especialmente en pacientes de edad avanzada. La superposición de múltiples comorbilidades añade mayor complejidad al escenario, exigiendo una atención meticulosa y experiencia. Este informe sirve como herramienta educativa para los expertos en oncología, así como testimonio de las complejidades de la atención al paciente en el entorno del diagnóstico y el tratamiento oncológico.

Linfoma anaplásico de grandes células T associado ao uso de implantes (BIA-ALCL): relato de caso / Implant-associated anaplastic large T-cell lymphoma (BIA-ALCL): case report

Reconhecido pela Organização Mundial de Saúde em 2016, o linfoma anaplásico de grandes células associado ao implante mamário (BIA-ALCL) é um subtipo incomum de linfoma não Hodgkin de células T, que se desenvolve após a inserção de próteses mamárias. A doença é uma afecção rara que afeta cerca de uma a cada 30.000 pessoas com implante mamário texturizado. As principais manifestações clínicas são o seroma tardio, assimetria mamária, massa e contratura capsular, com frequência mais elevada do primeiro. O explante da prótese com capsulectomia total pode ser suficiente para tratar o ALCL, com ressecções estendidas a locais adjacentes, quando necessário. Entretanto, em alguns casos, é realizada a radioterapia e/ou quimioterapia adjuvante. Conclui-se que, para um diagnóstico precoce e um tratamento efetivo, mulheres com seroma de aparecimento súbito e tardio deverão realizar exames complementares para a exclusão dessa afecção, mesmo com tempo inferior à média de desenvolvimento, que é de cerca de 10,6 anos.

Recognized by the World Health Organization in 2016, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon subtype of T-cell non-Hodgkin lymphoma that develops after the insertion of breast implants. The disease is a rare condition that affects approximately one in every 30,000 people with textured breast implants. The main clinical manifestations are late seroma, breast asymmetry, mass, and capsular contracture, with a higher frequency of the former. Explantation of the prosthesis with total capsulectomy may be sufficient to treat ALCL, with resections extended to adjacent sites when necessary. However, in some cases, adjuvant radiotherapy and/or chemotherapy is performed. It is concluded that, for an early diagnosis and effective treatment, women with sudden and late-onset seroma should undergo additional tests to exclude this condition, even with a shorter development time than the average, which is around 10.6 years.

Spontaneous laceration of spleen with hilar lymph node metastasis: a case of primary splenic mantle cell lymphoma in elderly

Mantle cell lymphoma (MCL) is a type of non-Hodgkin (B-cell) lymphoma (NHL) with manifestations ranging from indolent to aggressive disease. It arises from mantle zone or primary follicle lymphocytes and is associated with translocation t (11;14) which is seen in almost all cases. Most of the cases present at stage III/IV with hepatospenomegaly, generalized lymphadenopathy, bone marrow involvement or lymphoid polyposis. Rate of relapse is high occurring in 50-60% patients and 5-year survival rates are low ~27-30%. Median overall survival is 3.5 years. Age >60 years, raised serum LDH, high mitotic count, Ki67>30%, blastoid or pleomorphic variants, TP53 mutation, gains in 3q,11q and deletions of 13q as well as 17p are important prognostic factors associated with worst outcome. Treatment involves conventional chemo-immunotherapy and stem cell transplantation (SCT). In our case the elderly patient had an atraumatic splenic rupture with no past medical history of trauma. The patient presented to the emergency department with severe abdominal pain in left upper quadrant. Thus emergency splenectomy was executed successfully, and the patient was stabilized. After receiving initial cycle of R-CHOP regime, he was lost to follow up. In this case report, we will discuss the clinical presentation, as well as current treatment guidelines for atraumatic splenic rupture.

Linfomas no Hodgkin de células B en Panamá: realidad de un centro de referencia nacional / Non-Hodgkin B cell lymphomas in Panama. Describing the reality of a national reference center

Resumen Introducción. Los linfomas no Hodgkin (LNH) representan aproximadamente el 3% de todos los cánceres diagnosticados a nivel mundial y, dentro de las neoplasias linfoides, representan un 90% del total. Panamá no cuenta con ningún estudio epidemiológico sobre los LNH y tampoco se han publicado datos que evidencien nuestra realidad en cuanto a esta entidad neoplásica, por lo que resulta necesario conocer los datos de esta entidad heterogénea. Material y métodos. Estudio observacional, retrospectivo, analítico, de corte transversal realizado en un centro de tercer nivel de complejidad. La muestra del estudio corresponde a 196 pacientes. Se evaluaron los expedientes físicos y digitales de cada uno de los casos. La información recolectada fue analizada mediante el programa SPSS 25.0. El objetivo principal es determinar las características clínicas y epidemiológicas de los pacientes con LNH de células B incluidos en el estudio. Resultados. 53% de los pacientes incluidos en el estudio corresponden al sexo masculino y 47% al sexo femenino. 74.8% debutaron en estadios avanzados de la enfermedad, relacionado proablemente a que un porcentaje similiar reportó síntomas B. El linfoma difuso de células B grandes representa el subtipo más frecuente con más del 60% de los casos registrados. Valores de LDH >500 U/L y la presencia de síntomas B se asociaron a menor sobrevida global. Discusión. Las características epidemiológicas, clínicas y terapéuticas de nuestra población son similares a las descritas en la región. Sin embargo, existe una mayor proporción de pacientes que debutan con síntomas B y estadíos avanzados de la enfermedad. Se pudieron validar en nuestra población, factores de mal pronóstico descritos en otras latitudes.

Abstract Introduction. Non-Hodgkin lymphomas (NHL) represent approximately 3% of all cancers diagnosed worldwide and, within lymphoid neoplasms, they represent 90% of all cases. Panama does not have any epidemiological study on NHL and no data has been published that demonstrates our reality regarding this neoplastic entity, so it is necessary to know the data on this heterogeneous entity. Material and methods. Observational, retrospective, analytical, cross-sectional study carried out in a third level complexity center. The study sample corresponds to 196 patients. The records of each of the cases were evaluated. The information collected was analyzed using the SPSS 25.0 program. The main objective is to determine the clinical and epidemiological characteristics of patients with B-cell NHL included in the study. Results. 53% of the patients were male and 47% were female. 74.8% debuted in advanced stages of the disease, associated with a similar percentage reporting B symptoms. Diffuse large B cell lymphoma represents the most common subtype with more than 60% of registered cases. LDH values >500 U/L and the presence of B symptoms were associated with lower overall survival. Discussion. The epidemiological, clinical and therapeutic characteristics of our population are similar to those described in the region, however there is a greater proportion of patients who debut with B symptoms and advanced stages of the disease. It was possible to validate in our population poor prognostic factors that were described in other latitudes.

Características clínicas y respuesta al tratamiento del linfoma en personas que viven con el virus de la inmunodeficiencia humana (VIH) en un centro de referencia de Latinoamérica / Clinical characteristics and response to lymphoma treatment in people living with the human immunodeficiency virus (HIV) in a reference center in Latin America

Resumen Introducción. Los linfomas son neoplasias malignas caracterizadas por la proliferación clonal de linfocitos. Las personas portadoras del virus de inmunodeficiencia humana (VIH) desarrollan los subtipos más agresivos de linfoma. En México se conoce poco acerca de las características clínicas y la respuesta al tratamiento del linfoma en las personas que viven con el VIH. Material y métodos. Un estudio descriptivo, retrospectivo y transversal fue realizado en un hospital de referencia en el estado de Veracruz, México, la tercera entidad federativa mexicana con mayor número de casos de VIH. Pacientes ≥18 años, portadores del VIH y diagnosticados con linfoma no Hodgkin o Hodgkin entre junio 2017 a junio 2022 fueron incluidos en el estudio. Además del análisis descriptivo, se calcularon las curvas de KaplanMeier para la sobrevida y las hazard ratio (HR) mediante regresión de Cox para determinar el riesgo de muerte asociada a los diferentes factores. Resultados. Se analizó una cohorte de 32 personas que viven con el VIH con linfoma no Hodgkin (n= 30) o linfoma de Hodgkin (n= 2). El 90% del total de los pacientes fueron del sexo masculino con una mediana de edad de 39.3 años (25-68). El 40% de los pacientes presentó el linfoma y VIH al mismo tiempo, el 60% restante desarrollaron el linfoma en un período entre 1 y 22 años, con una media de tiempo de 6.8 años, de los cuales el 79% recibió terapia antirretroviral y registraba carga viral indetectable. El linfoma más frecuente fue el linfoma difuso de células grandes B (37.5%). La media de supervivencia global de los pacientes fue 6.65 años, con intervalos de confianza (IC) del 95% de 3.93 a 9.37 años con error estándar de 1.38 años; la probabilidad acumulada de supervivencia fue 0.4, con un error estándar de 0.1. En la regresión de Cox la albúmina ≤ 3 g/ dL tuvo un alto cociente de riesgo (HR= 5.69; IC 95%: 1.38-23.45, p= 0.016) para mortalidad, donde los pacientes con estos niveles de albúmina tuvieron una media de sobrevida de 9.8 meses. Discusión. A pesar de que los linfomas asociados a VIH son agresivos y se presentan en estadios avanzados, la sobrevida global alcanzada en este estudio fue similar a estudios previos. El esquema R-CHOP mostró buena respuesta en el LDCGB, pero continúa siendo controvertido el manejo de los otros tipos de linfoma. La hipoalbuminemia fue un factor de riesgo para mortalidad, por lo que podría incluirse en nuevas escalas pronósticas.

Abstract Introduction. Lymphomas are malignant neoplasms characterized by clonal proliferation of lymphocytes. Persons carrying the human immunodeficiency virus (HIV) develop the most aggressive subtypes of lymphoma. In Mexico, little is known about the clinical characteristics and response to treatment of lymphoma in people living with HIV. Material and methods. A descriptive, retrospective, cross-sectional study was conducted at a referral hospital in the state of Veracruz, Mexico, the third Mexican federative entity with the highest number of HIV cases. Patients ≥18 years old, HIV carriers and diagnosed with non-Hodgkin's or Hodgkin's lymphoma between June 2017 to June 2022 were included in the study. In addition to the descriptive analysis, Kaplan-Meier curves for survival and hazard ratio (HR) by Cox regression were calculated to determine the risk of mortality associated with the different factors. Results. A cohort of 32 people living with HIV with non-Hodgkin's lymphoma (n= 30) or Hodgkin's lymphoma (n= 2) was analyzed. Ninety percent of the total patients were male with a median age of 39.3 (25-68). The remaining 60% developed lymphoma in a period between 1 and 22 years, with a mean time of 6.8 years, of which 79% received antiretroviral therapy and had an undetectable viral load. The most frequent lymphoma was diffuse large B-cell lymphoma (37.5%). The mean overall survival of the patients was 6.65 years, with a 95% confidence interval (CI) of 3.93 to 9.37 years and standard error of 1.38 years; the cumulative probability of survival was 0.4, with a standard error of 0.1. In Cox regression albumin ≤ 3 g/dL had a high hazard ratio (HR= 5.69; 95% CI: 1.38-23.45, p= 0.016) for mortality, where patients with these albumin levels had a mean survival of 9.8 months. Discussion. Despite the fact that HIV-associated lymphomas are aggressive and present in advanced stages, the overall survival achieved in our unit is similar to that reported in the world literature. The R-CHOP scheme has a good response in DLBCL, but the management of other types of lymphoma remains controversial. Hypoalbuminemia was found to be the most important predictor of mortality, so it could be included in new prognostic scales.

Dual cutaneous lymphoid dyscrasias in a pediatric patient, with progression to mycosis fungoides: case report

This case report explores the progression of cutaneous lymphoid dyscrasia to a lymphoma in a 13-year-old boy with pityriasis lichenoides chronica and lichenoid pigmented purpuric dermatitis, the latter evolving into mycosis fungoides. We highlight some of the crucial clinical and histological characteristics to differentiate between these entities. Early identification of this progression is critical not only for preventing further lymphoma development but also for initiating prompt therapy.

Propuesta de estrategias terapéuticas combinadas para KRAS en cáncer de pulmón de células no pequeñas a partir de análisis in silico / Proposal of combined therapeutic strategies for KRAS in non-small cell lung cancer based on an in silico analysis

RESUMEN Objetivo: Los pacientes con cáncer de pulmón de células no pequeñas positivas a la mutación del gen linfoma anaplásico quinasa (ALK+) que, además, presentan mutaciones en el gen Kirsten rat sarcoma (KRAS), como KRASG12C, están mostrando resistencia tanto a inhibidores del gen linfoma anaplásico quinasa (ALK) como de KRAS. Por ello, se analizó la interacción de los inhibidores de ALK con KRAS, para sugerir una sinergia entre ambos. Materiales y métodos: En el estudio se realizó un modelado por homología de las estructuras KRASwt, KRASG12C y ALKwt. Posteriormente, se realizaron acoplamientos moleculares para determinar la energía de unión de los inhibidores de ALK y de KRAS, y evaluar la posible interacción entre los inhibidores de ALK con KRAS y la estructura KRASG12C. Finalmente, se analizó la expresión en la vía de proliferación celular de las proteínas rat sarcoma/quinasa regulada por señales extracelulares (vía RAS/MEK) mediante la técnica de Western blot. Resultados: Los valores de energía de unión muestran la posibilidad de interacción de los inhibidores de ALKwt, como crizotinib y alectinib, con las estructuras de KRASwt y KRASG12C. Los acoplamientos entre crizotinib con KRASwt y KRASG12C, respectivamente, muestran valores de energía de interacción (42,77 kcal/mol y 46,20 kcal/mol) muy similares a los obtenidos entre crizotinib y ALK (42,37 kcal/mol). A su vez, alectinib se acopló en el mismo sitio que los fármacos específicos de KRAS y KRASG12C, y presentaron valores de energía de interacción (51,74 kcal/mol y 54,69 kcal/mol, respectivamente) superiores a los obtenidos con ALK (44,94 kcal/mol). Finalmente, la expresión de la vía RAS/MEK nos mostró una disminución significativa de la expresión de RAS en líneas celulares de cáncer de pulmón ALK+ y ALKL1196M tratadas con crizotinib y alectinib. Conclusiones: Las técnicas in silico de este estudio muestran la posibilidad de acoplamiento entre los inhibidores de ALK (crizotinib y alectinib) con la estructura de KRAS. Esto permite sugerir una posible terapia combinada entre inhibidores de KRAS y ALK para los casos de coexistencia de ambas mutaciones, que puede evaluarse en posteriores ensayos con líneas celulares.

ABSTRACT Objective: Patients with non-small cell lung cancer positive for the anaplastic lymphoma kinase (ALK+) gene mutation who also have mutations in the Kirsten rat sarcoma (KRAS) gene, such as KRAS G12C, are showing resistance to both anaplastic lymphoma kinase (ALK) gene and KRAS inhibitors. Therefore, the interaction between ALK inhibitors and KRAS was analyzed to suggest a synergy between them. Materials and methods: The study performed homology modeling of the KRASwt, KRAS G12C and ALKwt structures. Subsequently, molecular dockings were carried out to determine the binding energy of ALK and KRAS inhibitors and to evaluate the possible interaction of ALK inhibitors with KRAS and the KRAS G12C structure. Finally, the expression in the RAS/MEK pathway was analyzed using the Western Blot technique. Results: The binding energy values show the potential interaction of ALKwt inhibitors, such as crizotinib and alectinib, with the KRASwt and KRAS G12C structures. The binding of crizotinib to KRASwt and KRAS G12C, respectively, indicates interaction energy values (42.77 kcal/mol and 46.20 kcal/mol) which are very similar to those obtained between crizotinib and ALK (42.37 kcal/mol). In turn, alectinib bound to the same site as drugs targeting KRAS and KRAS G12C, and showed interaction energy values (51.74 kcal/mol and 54.69 kcal/mol, respectively) higher than those obtained with ALK (44.94 kcal/mol). Finally, a significant decrease in RAS expression within the RAS/MEK pathway was observed in ALK+ and ALK 1196M lung cancer cell lines treated with crizotinib and alectinib. Conclusions: In silico techniques of this study demonstrate the potential binding of ALK inhibitors (crizotinib and alectinib) to the KRAS structure. In addition, this allows suggesting a possible combined therapy between KRAS and ALK inhibitors for cases of coexistence of both mutations that can be assessed in subsequent trials with cell lines.

Linfoma de células B primario de mama en una paciente con sida. Presentación de un caso y revisión de la literatura / Primary B-cell lymphoma of the breast in an AIDS patient. Case report and literature review

Los LNH constituyen la segunda neoplasia más frecuente en pacientes con VIH. Estas neoplasias están ligadas a la inmunodeficiencia, suelen ser de período de latencia prolongado y más frecuentes en hombres. Más del 95% de estas neoplasias son de fenotipo B, de alto grado de malignidad, extranodales y representan la causa de muerte en un 12% al 16% de los casos. El linfoma no Hodgkin primitivo de mama (LPM) es una entidad infrecuente, que representa el 2,2% de todos los linfomas extranodales y el 0,5% de todas las neoplasias malignas de la mama. Se presenta una mujer con sida y linfoma primario de mama. (AU)

NHL is the second most common neoplasm in patients with HIV. It is linked to immunodeficiency, tends to have a long latency period and is more common in men. More than 95% of these neoplasms are of phenotype B, high-grade, extranodal and are the cause of death in 12% to 16% of cases. Primitive non-Hodgkin lymphoma of the breast is a rare entity, accounting for 2.2% of all extranodal lymphomas and 0.5% of all breast malignancies. A woman with AIDS and primary breast lymphoma is presented. (AU)

Linfoma extranodal de epiglotis en un paciente con recaída de leucemia linfoide aguda de células T. Presentación de un caso / Extranodal lymphoma of the epiglottis in a patient with relapsed T-cell acute lymphoid leukemia. Case report

Los linfomas localizados en la laringe representan un porcentaje muy bajo dentro de los comprendidos en los tumores de cabeza y cuello en la edad pediátrica. El linfoma no Hodgkin es el subtipo más comúnmente reportado en la literatura, el cual dependiendo de su etiología y extensión determinará el pronóstico del paciente. La certeza del diagnóstico, que suele ser muy difícil de alcanzar, se confirma generalmente mediante una biopsia de tejido. En la actualidad, no hay reportes de la literatura acerca de linfomas leucemoides diseminados a laringe. Se presenta el caso de un paciente masculino adolescente de 17 años con diagnóstico de una leucemia linfoide aguda con recaída extra-nodal en la laringe por falla en el esquema quimioterapéutico instaurado.

Lymphomas located at the level of the larynx represent a very low percentage of head and neck tumors in the pediatric age group. Non-Hodgkin's lymphoma is the most reported subtype in the literature, which depending on its etiology and extension will determine the patient's prognosis. Diagnostic certainty, which is often very difficult to achieve, is usually confirmed by tissue biopsy. At present, there are no reports in the literature about leukemoid lymphomas disseminated to the larynx. We present the case of a 17-year-old adolescent male patient diagnosed with acute lymphoid leukemia with extranodal relapse in the larynx due to failure of the chemotherapeutic regimen.

Characterization, Antimicrobial and anticancer activity of biosynthesized silver nanoparticles using Garcinia gummi-gutta (L.) Robs. leaf extracts

Garcinia gummi-gutta is commercially an important plant as its leaves and fruits contain valuable chemical components and are used for various ailments and treatments. Even though, there are minimum reports that have been seen in their exploration of this plant in the field of nanotechnology. So the present study deals with the synthesis of silver nanoparticles from the aqueous and ethanol leaf extracts of G. gummi-gutta and screening its antimicrobial and anticancer properties. Green synthesized silver nanoparticles was characterized by UV-visible (UV-vis) spectroscopy, transmission electron microscopy (TEM), fourier transforms infrared spectroscopy (FTIR) and X-ray diffraction (XRD) studies. In UV-vis spectroscopy, the surface plasmon resonance (SPR) spectrum of silver nanoparticles produced prominent peaks at 365 and 363 nm in aqueous and ethanol leaf extracts of G. gummi-gutta, respectively. Scanning electron microscopy (SEM) and XRD studies showed that the biosynthesized silver nanoparticles from aqueous and ethanol extracts of G. gummi-gutta leaves are spherical and crystalline in nature with an average size of 25 and 23 nm. FTIR spectroscopy reveals that the functional groups are responsible for the synthesis and stabilization of silver nanoparticles. The biosynthesized silver nanoparticles from both plant extracts have remarkable antibacterial and anticancer properties. Through these studies, it was found that silver nanoparticles from the ethanol leaf extract of G. gummi-gutta is more potential than silver nanoparticles from the aqueous leaf extract of G. gummi-gutta. So the present study is a novel attempt to synthesize the silver nanoparticles from this plant and elucidate its antimicrobial and anticancer potential.

Enfermedad de Castleman: un enfoque integral a propósito de un reporte de caso / Castleman's Disease: A Comprehensive Approach Regarding a Case Report

Resumen Se presenta el caso clínico de una paciente del sexo femenino, de 30 años, con adenopatías supraclaviculares y axilares ipsilaterales, quien fue sometida a biopsia excisional con posterior estudio. El análisis histopatológico de la muestra de tejido resecado reveló una serie de características distintivas asociadas con la enfermedad de Castleman variante hialinovascular. La presentación de este caso no solo proporciona información detallada sobre la evolución clínica de la paciente, sino que también sirve como base para ilustrar los aspectos clave del diagnóstico histopatológico y las implicaciones inmunohistoquímicas en la enfermedad de Castleman. Además de hacer una revisión de tema respecto a esta patología poco común, en la cual los informes de casos son fundamentales para aumentar la comprensión de su variabilidad clínica y su abordaje diagnóstico, ilustrando los desafíos en el diagnóstico diferencial y como deben abordarse los mismos.

Abstract The clinical case of a 30-year-old female patient with supraclavicular and ipsilateral axillary lymphadenopathy who underwent excisional biopsy with subsequent study is presented. Histopathological analysis of the resected tissue sample revealed a series of distinctive features associated with hyalinevascular variant Castleman disease. The presentation of this case not only provides detailed information about the clinical evolution of the patient, but also serves as a basis to illustrate Key aspects of histopathological diagnosis and immunohistochemical implications in Castleman disease. In addition to making a review of the topic regarding this rare pathology in which case reports are essential to increase the understanding of its clinical variability and its diagnostic approach, illustrating the challenges in differential diagnosis and how they should be addressed.

Decrease of 5-hydroxymethylcytosine in primary cutaneous CD4+ small/medium sized pleomorphic T-cell lymphoproliferative disorder

Abstract Background: Primary cutaneous CD4+ small/medium-sized pleomorphic T-Cell lymphoproliferative disorder (PC-SMTLD) has been considered as a controversial dermatological disease that has been included in cutaneous T-cell lymphoma group, presenting most commonly as a solitary nodule and/or plaque with a specific and characteristic head and neck predilection. Due to the considerable overlap between PC-SMTLD and pseudolymphoma (PL), the differential diagnosis is often challenging. Methylation of DNA at position 5 of cytosine, and the subsequent reduction in intracellular 5-hydroxymethylcytosine (5-hmC) levels, is a key epigenetic event in several cancers, including systemic lymphomas. However, it has rarely been studied in cutaneous lymphomas. Objectives: The authors aimed to explore the role of differential 5-hmC immunostaining as a useful marker to distinguish PC-SMTLD from PL. Methods: Retrospective case series study with immunohistochemical and immunofluorescence analysis of 5-hmC was performed in PL and PC-SMTLD. Results: Significant decrease of 5-hmC nuclear staining was observed in PC-SMTLD when compared with PL (p<0.0001). By semi-quantitative grade integration, there were statistical differences in the final 5-hmC scores in the two study groups. The IF co-staining of 5-hmC with CD4 revealed a decrease of 5-hmC in CD4+ lymphocytes of PC-SMTLD. Study limitations: The small clinical sample size of the study. Conclusions: The immunorreactivity of 5-hmC in CD4+ lymphocytes was highly suggestive of a benign process as PL. Furthermore, the decrease of 5-hmC nuclear staining in PC-SMTLD indicated its lymphoproliferative status and helped to make the differential diagnosis with PL. © 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).

Effect of Modified Shenhong Tongluo Prescription on Cell Apoptosis in Rats with Myocardial Ischemia-reperfusion Injury by Bcl-2/Bax/Caspase-3 Signaling Pathway / 中国实验方剂学杂志

ObjectiveTo investigate the mechanism of modified Shenhong Tongluo prescription on cell apoptosis in rats with myocardial ischemia-reperfusion injury （MIRI）. MethodSixty Sprague-Dawley （SD） rats were randomly divided into a blank group， a model group， low-， medium-， and high-dose groups of modified Shenhong Tongluo prescription， and a simvastatin group. Except for the blank group， a rat model of MIRI was prepared by ligating the left anterior descending coronary artery. Starting from the first day after successful modeling， the blank group （1.0 mL·kg-1 physiological saline）， model group （1.0 mL·kg-1 physiological saline）， low-， medium-， and high-dose groups of modified Shenhong Tongluo prescription （1.031， 2.063， and 4.126 g·kg-1 Shenhong Tongluo prescriptiona standard concentrate）， and simvastatin group （0.71 mg·kg-1 simvastatin） were orally administered once daily for 2 weeks. Hematoxylin-eosin （HE） staining was used to observe the pathological changes of cardiomyocytes. Enzyme-linked immunosorbent assay （ELISA） was used to detect the levels of serum creatine kinase isoenzyme （CK-MB）， interleukin-6 （IL-6）， and tumor necrosis factor-α （TNF-α）. TdT-mediated dUTP nick-end labeling（TUNEL） staining was used to detect the apoptosis rate of rat cardiomyocytes. Western blot was used to detect the expression levels of apoptosis-related proteins B-cell lymphoma-2 （Bcl-2）， Bcl-2-associated X protein （Bax）， and caspase-3. ResultCompared with the blank group， in the model group， HE staining showed disturbed arrangement of cardiomyocytes， incomplete fibers， focal necrosis of cardiomyocytes， and inflammatory cell infiltration； serum CK-MB， IL-6， and TNF-α levels were significantly increased （P<0.05）； apoptosis rate of cardiomyocytes was significantly increased （P<0.01）， with significantly increased expression levels of Bax and Caspase-3 proteins， and significantly decreased Bcl-2 expression （P<0.05）. Compared with the model group， the low-， medium-， and high-dose groups of modified Shenhong Tongluo prescription significantly reduced CK-MB， IL-6， and TNF-α levels （P<0.05）， significantly downregulated cardiomyocyte apoptosis rate （P<0.05）， significantly decreased Bax and Caspase-3 proteins， and significantly increased Bcl-2 expression levels （P<0.01）. In the modified Shenhong Tongluo prescription groups， the expression levels of Bax and Caspase-3 proteins significantly decreased with increasing dosage， while the expression level of Bcl-2 significantly increased with increasing dosage of modified Shenhong Tongluo prescription （P<0.05）. ConclusionShenhong Tongluo prescription can alleviate myocardial tissue pathological damage and reduce myocardial cell apoptosis， possibly by inhibiting Caspase-3 and Bax expression and promoting Bcl-2 expression.

Effect of ADU-S100/doxorubicin in situ vaccine on diffuse large B-cell lymphoma and its mechanism / 白血病·淋巴瘤

Objective:To explore the antitumor effect of ADU-S100/doxorubicin in situ vaccine on diffuse large B-cell lymphoma (DLBCL) and its mechanism.Methods:The 6-week-old female BALB/c mice were selected, and the bilateral murine subcutaneous B-cell lymphoma model was established with murine B-cell lymphoma A20 cells. The subcutaneous tumor-bearing mice were randomly divided into untreated group (without treatment), ADU-S100 in situ vaccine treatment group (intratumoral injection of interferon gene stimulating factor agonist ADU-S100), doxorubicin in situ vaccine treatment group (intratumoral injection of doxorubicin), and ADU-S100/doxorubicin in situ vaccine treatment group (intratumoral injection of ADU-S100 and doxorubicin) by using random number table method, with 5 mice in each group. The right tumors of the bilateral subcutaneous tumor-bearing mice were defined as proximal tumors, and the left tumors of the bilateral subcutaneous tumor-bearing mice were defined as distal tumors. Only the proximal tumors were treated via the intratumoral route, and the distal tumors were not treated. On day 23 after tumor inoculation, the percentages of CD11c + dendritic cells (DC), CD8 + CD11c + DC and CD80 + CD11c + DC in the spleen of mice in each group were detected by flow cytometry. The splenocytes of mice in each group were stimulated with A20 tumor cell lysate in vitro, the percentages of 5'-ethynyl-2'-deoxyuridine-positive (EdU +) cells and tumor necrosis factor-α-positive (TNF-α +) cells in CD8 + T cells in each in situ vaccine treatment group were detected by flow cytometry, and the killing effect of cytotoxic T lymphocyte (CTL) in each group was measured by using the lactate dehydrogenase (LDH) cytotoxicity assay kit. The mice treated with ADU-S100/doxorubicin in situ vaccine were intraperitoneally injected with anti-mouse CD8α (clone 53-6.7) mAb or isotype control on days 7, 12 and 17 after tumor inoculation to eliminate CD8 + cells. On day 23 after tumor inoculation, the proximal and distal tumor volumes of mice in the ADU-S100/doxorubicin in situ vaccine combined with anti-mouse CD8α (clone 53-6.7) mAb or isotype control treatment group were measured, the percentages of CD8 + T cells and CD8 + CD11c + DC in the spleen of tumor-bearing mice in these two groups were detected by flow cytometry, and the infiltration of CD8 + T cells in the tumor tissues from these two groups was detected by immunohistochemistry (IHC) staining. Results:On days 11, 14, 17, 20 and 23 after tumor inoculation, the proximal and distal tumor volumes of mice in each treated group were lower than those in the untreated group (all P < 0.05). The proportions of CD11c + DC in the spleen of the untreated group, ADU-S100 in situ vaccine treatment group, doxorubicin in situ vaccine treatment group and ADU-S100/doxorubicin in situ vaccine treatment group were (4.92±0.63)%, (7.54±0.84)%, (7.45±0.86)% and (11.63±0.85)%, respectively, and the difference was statistically significant ( F = 72.30, P < 0.001); the proportions of CD8 + CD11c + DC were (1.36±0.34)%, (4.02±0.43)%, (4.22±0.61)% and (6.11±0.73)%, respectively, and the difference was statistically significant ( F = 76.09, P < 0.001); the proportions of CD80 + CD11c + DC were (0.51±0.24)%, (1.69±0.23)%, (1.82±0.25)% and (4.09±0.39)%, respectively, and the difference was statistically significant ( F = 167.40, P < 0.001). The CTL responses and the proportion of EdU + cells and TNF-α + cells in CD8 + T cells in each in situ vaccine treatment group were higher than those in the untreated group (all P < 0.05). Furthermore, the enhanced CTL responses and the increased proportion of EdU + cells and TNF-α + cells in CD8 + T cells were observed in the ADU-S100/doxorubicin in situ vaccine treatment group as compared to the ADU-S100 in situ vaccine treatment group and doxorubicin in situ vaccine treatment group (all P < 0.05). The proportions of CD8 + T cells and CD8 + CD11c + DC in the spleen of mice treated with ADU-S100/doxorubicin in situ vaccine and anti-mouse CD8α mAb were lower than those in ADU-S100/doxorubicin in situ vaccine and isotype control group (both P < 0.05) and both proximal and distal tumor volumes of mice treated with ADU-S100/doxorubicin in situ vaccine and anti-mouse CD8α mAb were larger than those in ADU-S100/doxorubicin in situ vaccine and isotype control group (both P < 0.05). Conclusions:ADU-S100/doxorubicin in situ vaccine can induce profound regression of proximal tumors in bilateral murine subcutaneous B-cell lymphoma model and generate systemic immune responses capable of partially inhibiting distant tumor growth, and the antitumor efficacy of ADU-S100/doxorubicin in situ vaccine may require CD8 + CD11c + DC-mediated CD8 + T cell immune responses.

Human immunodeficiency virus-associated Hodgkin lymphoma: a clinical analysis of 22 cases / 白血病·淋巴瘤

Objective:To investigate the clinical characteristics, therapeutic efficacy and prognosis of patients with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.Methods:A retrospective case series study was conducted. The clinical data of 22 HIV-associated Hodgkin lymphoma patients in Chongqing University Cancer Hospital from December 2013 to June 2022 were retrospectively analyzed. Their clinical features, laboratory results, treatment, and prognosis were analyzed. Kaplan-Meier method was used to perform survival analysis.Results:The age [ M ( Q1, Q3)] of 22 patients was 44 years old (36 years old, 53 years old); 18 cases were male, 4 cases were female; clinical staging was stage Ⅲ in 5 patients and stage Ⅱ in 17 patients. All 22 patients were infected with HIV through sexual transmission, with 10 cases transmitted through man sex with man and 12 cases transmitted through heterosexual transmission. Nine patients were found to be infected with HIV at the time of diagnosis of lymphoma, and 13 patients presented with lymphoma at 22.2 months (12.3 months, 38.4 months) after diagnosis of HIV infection. Of the 22 patients, 3 abandoned treatment; 19 patients were treated with antiretroviral therapy combined with ABVD regimen chemotherapy, 9 patients had complete remission, and 10 patients had partial remission. After follow-up of 46.8 months (24.8 months, 64.5 months), the 5-year progression-free survival rate was 83.9%, and the 5-year overall survival rate was 89.5%. Conclusions:HIV-associated Hodgkin lymphoma exhibits an invasive process in clinical practice, and standardized antiretroviral therapy combined with ABVD regimen chemotherapy can lead to long-term survival for patients.